Group 1 - Singapore's Government Investment Corporation (GIC) increased its stake in HAPO Pharmaceuticals by acquiring 690,000 shares at an average price of HKD 13.5791 per share, totaling approximately HKD 9.37 million [2] - Following this purchase, GIC's holdings in HAPO Pharmaceuticals rose to 62.975 million shares, increasing its ownership percentage from 6.97% to 7.05% [2] - GIC has made multiple purchases of HAPO Pharmaceuticals this year, including a significant acquisition of 4.0222 million shares for approximately HKD 511 million on August 29, which raised its ownership from 1.62% to 6.37% [2] Group 2 - HAPO Pharmaceuticals has experienced a remarkable revenue increase of 243% over the past year, significantly outpacing the industry growth rate [3] - Despite this substantial revenue growth, HAPO Pharmaceuticals' price-to-earnings ratio remains below the average for the biotechnology industry, indicating considerable future growth potential [3]
新加坡投资巨头接连出手 和铂医药持续获GIC增持